Prestige Consumer Healthcare Stock Forecast, Price & News

Prestige Consumer Healthcare's stock was trading at $35.91 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, PBH shares have decreased by 4.8% and is now trading at $34.17.
View which stocks have been most impacted by COVID-19.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Prestige Consumer Healthcare in the last year. There are currently 6 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Prestige Consumer Healthcare.

Prestige Consumer Healthcare is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020.
View our earnings forecast for Prestige Consumer Healthcare.

Prestige Consumer Healthcare will be holding an earnings conference call on Thursday, November 5th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Prestige Consumer Healthcare Inc. (NYSE:PBH) announced its earnings results on Thursday, August, 6th. The company reported $0.86 EPS for the quarter, beating the consensus estimate of $0.70 by $0.16. The business had revenue of $229.40 million for the quarter, compared to the consensus estimate of $221.27 million. Prestige Consumer Healthcare had a net margin of 15.84% and a return on equity of 13.81%. The business's revenue for the quarter was down 1.2% on a year-over-year basis. During the same period in the prior year, the company earned $0.65 earnings per share.
View Prestige Consumer Healthcare's earnings history.

Prestige Consumer Healthcare updated its second quarter earnings guidance on Thursday, August, 6th. The company provided earnings per share guidance of $0.70 or more for the period, compared to the Thomson Reuters consensus estimate of $0.71. The company issued revenue guidance of $225 million or more, compared to the consensus revenue estimate of $236.06 million.

7 brokerages have issued twelve-month target prices for Prestige Consumer Healthcare's shares. Their forecasts range from $43.00 to $97.00. On average, they anticipate Prestige Consumer Healthcare's stock price to reach $69.00 in the next twelve months. This suggests a possible upside of 101.9% from the stock's current price.
View analysts' price targets for Prestige Consumer Healthcare.

Some companies that are related to Prestige Consumer Healthcare include The Estée Lauder Companies (EL), Herbalife Nutrition (HLF), Nu Skin Enterprises (NUS), USANA Health Sciences (USNA), Medifast (MED), Inter Parfums (IPAR), Revlon (REV), Nature's Sunshine Products (NATR) and Veru (VERU).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Prestige Consumer Healthcare investors own include Pfizer (PFE), AbbVie (ABBV), Gilead Sciences (GILD), AT&T (T), Intel (INTC), ONEOK (OKE), Wells Fargo & Company (WFC), International Business Machines (IBM), Micron Technology (MU) and Teva Pharmaceutical Industries (TEVA).

Prestige Consumer Healthcare trades on the New York Stock Exchange (NYSE) under the ticker symbol "PBH."

Prestige Consumer Healthcare's stock is owned by many different retail and institutional investors. Top institutional shareholders include LSV Asset Management (1.45%), Wedge Capital Management L L P NC (0.57%), Dalton Greiner Hartman Maher & Co. (0.36%), Peregrine Capital Management LLC (0.27%), Skyline Asset Management LP (0.18%) and Nisa Investment Advisors LLC (0.05%). Company insiders that own Prestige Consumer Healthcare stock include Paton Brett, Ronald M Lombardi and Timothy Connors.
View institutional ownership trends for Prestige Consumer Healthcare.

PBH stock was sold by a variety of institutional investors in the last quarter, including Dalton Greiner Hartman Maher & Co., Peregrine Capital Management LLC, Nisa Investment Advisors LLC, Envestnet Asset Management Inc., Denali Advisors LLC, State of Alaska Department of Revenue, and Skyline Asset Management LP.
View insider buying and selling activity for Prestige Consumer Healthcare.

PBH stock was acquired by a variety of institutional investors in the last quarter, including Pacer Advisors Inc., Wedge Capital Management L L P NC, Bowling Portfolio Management LLC, LSV Asset Management, Foundry Partners LLC, and Diversified Trust Co.
View insider buying and selling activity for Prestige Consumer Healthcare.

Shares of PBH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of PBH stock can currently be purchased for approximately $34.17.

Prestige Consumer Healthcare has a market capitalization of $1.71 billion and generates $963.01 million in revenue each year. The company earns $142.28 million in net income (profit) each year or $2.96 on an earnings per share basis. Prestige Consumer Healthcare employs 520 workers across the globe.

The official website for Prestige Consumer Healthcare is www.prestigebrands.com.

Prestige Consumer Healthcare's mailing address is 660 WHITE PLAINS ROAD SUITE 250, TARRYTOWN NY, 10591. The company can be reached via phone at 914-524-6800 or via email at [email protected]